Company research
SOPHiA GENETICS SA
CIK 1840706Updated Nov 10, 2026
SecuritySOPH · NASDAQ · equity
SOPH price & chart
Loading TradingView…
NASDAQ:SOPH on TradingView ↗About the company
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.
In the news
SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan USA - English USA - Deutsch USA - Nederlands USA - Français USA - English News provided by SOPHiA GENETICS Jan 12, 2026, 07:00 ET Share this arti ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -78,999,000Source | -62,493,000Source | -78,981,000Source | -87,449,000Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | 84,000Source | 155,000Source | 40,000Source | -328,000Source |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -6,603,000Source | 5,892,000Source | -6,500,000Source | 1,332,000Source |
| AdjustmentsForDeferredTaxOfPriorPeriodsUSD | — | 0Source | 0Source | -509,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 16,205,000Source | 16,488,000Source | 15,242,000Source | 13,613,000Source |
| GeneralAndAdministrativeExpenseUSD | 52,563,000Source | 46,953,000Source | 53,301,000Source | 55,816,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | 200,000Source | 536,000Source | 801,000Source | 0Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 3,953,000Source | — | — | — |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | 1,728,000Source | 6,000Source | 266,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | — | 3,421,000Source | 4,655,000Source | 1,265,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 1,872,000Source | 2,750,000Source | 3,043,000Source | 2,316,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 34,563,000Source | 13,930,000Source | — | 0Source |
| ProceedsFromIssuingSharesUSD | 1,093,000Source | — | — | 0Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 108,000Source | 195,000Source | 263,000Source | 464,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 0Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Total Revenue | — | — | — | — |
| Additional Financial Items | ||||
| AdministrativeExpenseUSD | — | — | — | 6,635,000Source |
| BasicEarningsLossPerShareUSD per share | -1.17Source | -0.95Source | -1.22Source | -1.36Source |
| CurrentTaxExpenseIncomeUSD | 1,458,000Source | 1,115,000Source | 215,000Source | 310,000Source |
| DeferredTaxExpenseIncomeUSD | -30,000Source | -47,000Source | 231,000Source | -118,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | -30,000Source | -47,000Source | 180,000Source | -117,000Source |
| DepreciationRightofuseAssetsUSD | 2,200,000Source | 2,640,000Source | 3,646,000Source | 2,500,000Source |
| DilutedEarningsLossPerShareUSD per share | -1.17Source | -0.95Source | -1.22Source | -1.36Source |
| EmployeeBenefitsExpenseUSD | — | 56,900,000Source | 60,323,000Source | 59,333,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 93,657,000Source | 83,902,000Source | 87,521,000Source | 84,426,000Source |
| GeneralAndAdministrativeExpenseUSD | 52,563,000Source | 46,953,000Source | 53,301,000Source | 55,816,000Source |
| GrossProfitUSD | 52,077,000Source | 43,937,000Source | 42,913,000Source | 31,254,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillUSD | 0Source | 0Source | 0Source | 0Source |
| IncomeTaxExpenseContinuingOperationsUSD | 1,512,000Source | 1,223,000Source | 486,000Source | -136,000Source |
| InterestExpenseUSD | 4,554,000Source | 1,913,000Source | 588,000Source | 639,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 573,000Source | 567,000Source | 545,000Source | 422,000Source |
| OtherOperatingIncomeExpenseUSD | -86,000Source | 183,000Source | 954,000Source | 377,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | 1,867,000Source | 2,661,000Source | 1,735,000Source | 2,005,000Source |
| ProfessionalFeesExpenseUSD | — | 10,987,000Source | 14,245,000Source | 13,837,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -78,999,000Source | -62,493,000Source | -78,981,000Source | -87,449,000Source |
| ProfitLossBeforeTaxUSD | -77,487,000Source | -61,270,000Source | -78,495,000Source | -87,585,000Source |
| ProfitLossFromOperatingActivitiesUSD | -70,906,000Source | -66,568,000Source | -74,826,000Source | -87,823,000Source |
| ResearchAndDevelopmentExpenseUSD | 34,216,000Source | 34,366,000Source | 36,969,000Source | 35,371,000Source |
| RevenueFromInterestUSD | 1,872,000Source | 3,362,000Source | 4,547,000Source | 1,324,000Source |
Filing attachments
d25509dex991.htm · 6-K · 2026-06-22
Exhibit 99.1 SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ - SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and com…
Read attachment ↗d25509dex992.htm · 6-K · 2026-06-22
Exhibit 99.2 SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ - SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting di…
Read attachment ↗